These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 11557496)

  • 1. Comparison of once-daily versus twice-daily administration of cefdinir against typical bacterial respiratory tract pathogens.
    Ross GH; Hovde LB; Ibrahim KH; Ibrahim YH; Rotschafer JC
    Antimicrob Agents Chemother; 2001 Oct; 45(10):2936-8. PubMed ID: 11557496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contemporary evaluation of the in vitro activity and spectrum of cefdinir compared with other orally administered antimicrobials tested against common respiratory tract pathogens (2000-2002).
    Sader HS; Fritsche TR; Mutnick AH; Jones RN
    Diagn Microbiol Infect Dis; 2003 Nov; 47(3):515-25. PubMed ID: 14596971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of cefdinir against respiratory pathogens isolated in Sicily with reference to beta-lactamase production.
    Blandino G; Aleo G; Caccamo F; Nicolosi VM; Siracusa V; Speciale A
    J Chemother; 1996 Jun; 8(3):193-9. PubMed ID: 8808715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In-vitro antimicrobial activity of 7432-S (SCH39720) against commonly isolated respiratory tract pathogens.
    Jones RN; Barry AL
    J Antimicrob Chemother; 1988 Sep; 22(3):387-9. PubMed ID: 3141348
    [No Abstract]   [Full Text] [Related]  

  • 5. Activity of once-daily cefpodoxime regimens against Haemophilus influenzae and Streptococcus pneumoniae with an in vitro pharmacodynamic chamber model.
    Garrison MW; Malone CL; Eiland JE
    Antimicrob Agents Chemother; 1996 Jun; 40(6):1545-7. PubMed ID: 8726036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
    Granizo JJ; Giménez MJ; Barberán J; Coronel P; Gimeno M; Aguilar L
    Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative kill and growth rates determined with cefdinir and cefaclor and with Streptococcus pneumoniae and beta-lactamase-producing Haemophilus influenzae.
    Yourassowsky E; Van der Linden MP; Crokaert F
    Antimicrob Agents Chemother; 1992 Jan; 36(1):46-9. PubMed ID: 1590698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Five-day twice daily cefdinir therapy for acute otitis media: microbiologic and clinical efficacy.
    Block SL; Hedrick JA; Kratzer J; Nemeth MA; Tack KJ
    Pediatr Infect Dis J; 2000 Dec; 19(12 Suppl):S153-8. PubMed ID: 11144397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of oral antibiotics against respiratory tract pathogens in Spain.
    Calvo A; Amores R; Valero E; Fuentes F; Gómez-Lus ML; Prieto J;
    Rev Esp Quimioter; 2003 Dec; 16(4):436-43. PubMed ID: 14961138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Antimicrobial activities of cefetamet against clinically isolated strains from community acquired respiratory tract infections. Part III].
    Matsumoto Y; Ishihara R; Suzuki Y; Nishinari C; Ishii Y; Nakane Y; Endo H
    Jpn J Antibiot; 1999 Jun; 52(6):469-77. PubMed ID: 10481811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimicrobial activity of the new macrolide flurithromycin against Haemophilus influenzae, Streptococcus pneumoniae, Streptococcus pyogenes, Branhamella catarrhalis and Staphylococcus aureus.
    Nord CE; Lindmark A; Persson I
    J Chemother; 1989 Jul; 1(4 Suppl):203-4. PubMed ID: 16312369
    [No Abstract]   [Full Text] [Related]  

  • 12. Macrolide resistance in Streptococci and Haemophilus influenzae.
    Bozdogan B; Appelbaum PC
    Clin Lab Med; 2004 Jun; 24(2):455-75. PubMed ID: 15177849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of cefditoren and other comparators against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis causing community-acquired respiratory tract infections in China.
    Yang Q; Xu Y; Chen M; Wang H; Sun H; Hu Y; Zhang R; Duan Q; Zhuo C; Cao B; Liu Y; Yu Y; Sun Z; Chu Y
    Diagn Microbiol Infect Dis; 2012 Jun; 73(2):187-91. PubMed ID: 22521692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Activity of telithromycin and other oral antibiotics against respiratory tract pathogens with acquired mechanisms of resistance].
    Gómez-Garcés JL; Alós JI; Hernáiz C; Gómez C
    Enferm Infecc Microbiol Clin; 2004; 22(6):323-7. PubMed ID: 15228898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibiotic susceptibility in Streptococcus pneumoniae, Haemophilus influenzae and Streptococcus pyogenes in Pakistan: a review of results from the Survey of Antibiotic Resistance (SOAR) 2002-15.
    Zafar A; Hasan R; Nizamuddin S; Mahmood N; Mukhtar S; Ali F; Morrissey I; Barker K; Torumkuney D
    J Antimicrob Chemother; 2016 May; 71 Suppl 1(Suppl 1):i103-9. PubMed ID: 27048578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative in vitro activity of telithromycin and beta-lactam antimicrobials against community-acquired bacterial respiratory tract pathogens in the United States: findings from the PROTEKT US study, 2000-2001.
    Stratton CW; Brown SD
    Clin Ther; 2004 Apr; 26(4):522-30. PubMed ID: 15189749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postantibiotic effect of ceftibuten on respiratory pathogens.
    Chin NX; Huang HB; Neu HC
    Pediatr Infect Dis J; 1995 Jul; 14(7 Suppl):S84-7. PubMed ID: 7567315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cefdinir: a review of its use in the management of mild-to-moderate bacterial infections.
    Perry CM; Scott LJ
    Drugs; 2004; 64(13):1433-64. PubMed ID: 15212560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Antimicrobial susceptibility of Streptococcus pyogenes, Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis from community acquired respiratory infections in 2000].
    Melo-Cristino J; Fernandes ML; Serrano N;
    Acta Med Port; 2001; 14(5-6):459-68. PubMed ID: 11878155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of the dietary compound L-sulforaphane against respiratory pathogens.
    Mazarakis N; Higgins RA; Anderson J; Toh ZQ; Luwor RB; Snibson KJ; Karagiannis TC; Do LAH; Licciardi PV
    Int J Antimicrob Agents; 2021 Dec; 58(6):106460. PubMed ID: 34695564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.